Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Hannes KehmDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0003-1299-4754
Stefan ZensDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0003-0538-9652
Daniel BaumannDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0003-4484-9973
Zibo MengDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0002-6690-7380
Arnoud H de RuCenter for Medical Systems Biology, Leiden University Medical Center, Leiden, Netherlands.ORCID 0009-0002-1166-4059
Rayman T N TjokrodirijoCenter for Medical Systems Biology, Leiden University Medical Center, Leiden, Netherlands.
Caroline VentDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0002-6883-2666
Olga MurawjewDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0008-9445-1641
Sarah BraunDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0009-9244-1033
Anne WeissDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0001-8270-9256
Florian BieberichDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0002-6678-5985
Aline KonradDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0003-3528-7227
Francesca LucatoDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0009-3504-973X
Janne KühnerDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0009-8643-8057
Sonia Gutierrez MinguezDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0009-0007-8589-4419
Chin Leng TanDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0002-2529-1030
Jonas D FörsterFaculty of Biosciences, Heidelberg University, Heidelberg 69120, Germany.ORCID 0000-0003-3437-6738
Mogjiborahman SalekDivision of Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.ORCID 0000-0002-6664-4752
Angelika B RiemerDivision of Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.ORCID 0000-0002-5865-0714
Michael VolkmarDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0001-5970-1053
Peter van VeelenCenter for Medical Systems Biology, Leiden University Medical Center, Leiden, Netherlands.ORCID 0000-0002-7898-9408
Isabel PoschkeDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0002-4387-5566
Rienk OffringaDivision of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0001-6310-1026
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Although pancreatic cancer is generally refractory to immune checkpoint blockade, recent studies of tumor-infiltrating T cells in human tumor samples demonstrated the presence of in vivo expanded, tumor-reactive T cell receptor (TCR) clonotypes. Here, we explored the T cell repertoire in a murine pancreatic cancer model by combining single-cell transcriptomics with functional TCR characterization. This uncovered a substantial diversity of tumor-reactive TCR clonotypes. Whereas some of these were exclusively reactive against the autologous tumor, most TCRs reacted against syngeneic tumor cells of diverse tissue origin. Immunopeptidome analyses revealed three T cell epitopes reflecting distinct tumor antigen classes also found in human cancers: a mutanome-encoded neoantigen, an epitope encoded by an ectopically expressed endogenous retroviral provirus, and an epitope derived from a cell stress-induced autoantigen. These findings underline the importance of uncovering the antigen specificity of the natural tumor-reactive TCR repertoire to assess its therapeutic potential and safety with regard to personalized immunotherapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire. · full record | OpenQuestion